Ornella C. Weideli
Ornella C. Weideli has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Christoph H. Saely
Private University in the Principality of Liechtenstein,Triesen,Liechtenstein; Vorarlberg Institute for Vascular Investigation and Treatment,Feldkirch,Austria; Department of Internal Medicine I,Academic Teaching Hospital Feldkirch,Feldkirch,Austria, Liechtenstein
1 shared publication - David Conen
Population Health Research Institute, McMaster University, Hamilton, Canada
1 shared publication - Jens Kuhle
Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Switzerland; and
1 shared publication - Julia Telser
Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein
1 shared publication - Kirsten Grossmann
Institute of Laboratory Medicine (ILM),Private University in the Principality of Liechtenstein,Triesen,Liechtenstein; Dr Risch Medical Laboratory, Sonic Suisse SA,Vaduz,Liechtenstein; Translational Medicine at Interfaces (TMG),Davos Wolfgang,Switzerland, Switzerland
1 shared publication - Lorenz Risch
Institute of Laboratory Medicine (ILM),Private University in the Principality of Liechtenstein,Triesen,Liechtenstein; Dr Risch Medical Laboratory, Sonic Suisse SA,Vaduz,Liechtenstein; Center of Laboratory Medicine,University Institute of Clinical Chemistry, University of Bern, Inselspital,Bern,Switzerland, Liechtenstein
1 shared publication
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Preprints.org
Neurological Biomarker Analysis Reveals Smoking-Related GFAP Alterations Independent of Sleep Apnea
Background: Obstructive sleep apnea (OSA) and smoking are associated with oxidative stress, neuronal damage and cardiovascular risk. This study investigated whether subclinical sleep apnea (SSA) - undiagnosed sleep-disordered breathing - or smoking exposure and nicotine dependence are associated with serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in young, healthy adults. Method: This cross-sectional analysis included 1,125 participants from the population-based GAPP cohort (mean age 34.4 years; 51.8% female). SSA was defined as an oxygen desaturation index (ODI; number of ≥4% oxygen desaturations per hour) and/or a respiratory event index (REI; number of apneas and hypopneas per hour) of ≥5. Smoking exposure and nicotine dependence was assessed by smoking years, pack-years, and the Fagerström Test for Nicotine Dependence (FTND). Associations with serum GFAP and NfL levels were investigated using ANCOVA models adjusted for relevant confounders. Results: SSA was present in 4.5% of participants. Current and former smoking prevalence were 20.8% and 22%, respectively. GFAP levels were higher among participants with SSA, but neither GFAP nor NfL was significantly associated with SSA. In contrast, smoking exposure and nicotine dependence were inversely associated with GFAP concentrations, with smoking years remaining significant across adjusted models, whereas NfL levels showed no significant associations with smoking measures. Conclusion: In young, healthy adults, SSA was not associated with GFAP or NfL levels, whereas smoking measures were independently associated with lower GFAP concentrations but not with NfL levels, suggesting smoking-related biological processes may affect astrocytic and axonal biomarkers differently in early adulthood.
- 18 November 2026
- Published by MDPI AG in Preprints.org
Open AccessNeurological Biomarker Analysis Reveals Smoking-Related GFAP Alterations Independent of Sleep Apnea
Background: Obstructive sleep apnea (OSA) and smoking are associated with oxidative stress, neuronal damage and cardiovascular risk. This study investigated whether subclinical sleep apnea (SSA) - undiagnosed sleep-disordered breathing - or smoking exposure and nicotine dependence are associated with serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in young, healthy adults. Method: This cross-sectional analysis included 1,125 participants from the population-based GAPP cohort (mean age 34.4 years; 51.8% female). SSA was defined as an oxygen desaturation index (ODI; number of ≥4% oxygen desaturations per hour) and/or a respiratory event index (REI; number of apneas and hypopneas per hour) of ≥5. Smoking exposure and nicotine dependence was assessed by smoking years, pack-years, and the Fagerström Test for Nicotine Dependence (FTND). Associations with serum GFAP and NfL levels were investigated using ANCOVA models adjusted for relevant confounders. Results: SSA was present in 4.5% of participants. Current and former smoking prevalence were 20.8% and 22%, respectively. GFAP levels were higher among participants with SSA, but neither GFAP nor NfL was significantly associated with SSA. In contrast, smoking exposure and nicotine dependence were inversely associated with GFAP concentrations, with smoking years remaining significant across adjusted models, whereas NfL levels showed no significant associations with smoking measures. Conclusion: In young, healthy adults, SSA was not associated with GFAP or NfL levels, whereas smoking measures were independently associated with lower GFAP concentrations but not with NfL levels, suggesting smoking-related biological processes may affect astrocytic and axonal biomarkers differently in early adulthood.